当前位置: X-MOL 学术Bioorg. Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Structure-based drug design of 1,3,6-trisubstituted 1,4-diazepan-7-ones as selective human kallikrein 7 inhibitors
Bioorganic & Medicinal Chemistry Letters ( IF 2.5 ) Pub Date : 2018-03-03 , DOI: 10.1016/j.bmcl.2018.03.011
Hidenobu Murafuji , Hiroki Sakai , Megumi Goto , Yoshiaki Oyama , Seiichi Imajo , Hajime Sugawara , Toshiyuki Tomoo , Tsuyoshi Muto

A novel series of 1,3,6-trisubstituted 1,4-diazepan-7-ones were investigated as human kallikrein 7 (KLK7, stratum corneum chymotryptic enzyme) inhibitors. Based on the X-ray co-crystal structure of compound 1 bound to human KLK7, the derivatives of this scaffold were designed, synthesized, and evaluated. Through structure-activity relationship studies focused on the side chain located in the prime site region of the enzyme, representative compounds 15, 33a, and 35a were identified as highly potent and selective inhibitors of human KLK7.



中文翻译:

1,3,6-三取代的1,4-二氮杂潘-7-酮作为选择性人激肽释放酶7抑制剂的基于结构的药物设计

研究了一系列新的1,3,6-三取代的1,4-二氮杂-7-酮类化合物,作为人激肽释放酶7(KLK7,角质层胰凝乳蛋白酶)抑制剂。根据与人KLK7结合的化合物1的X射线共晶体结构,设计,合成和评估该支架的衍生物。通过结构-活性关系研究集中在位于所述酶的主要位点区域中的侧链,代表性的化合物1533A,和35A被鉴定为人类KLK7的高度有效的和选择性的抑制剂。

更新日期:2018-03-03
down
wechat
bug